Study S000321

A Multicenter, Randomized, Active-Controlled, Open-Label Phase IIb Study Evaluating Safety and Tolerability of Switching to Zovaglutide Injection After Titration to 2.4 mg Semaglutide Injection (Wegovy®) in Adults With Obesity (HORIZON-SWITCH-SZ)

ClinicalTrials.gov record

Registration

Registration: NCT07812597
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 210
Start: 2026-10-12
Primary completion: 2028-01-13
Lead sponsor: Beijing QL Biopharmaceutical Co.,Ltd
Conditions: Obesity
Interventions: DRUG:zovaglutide Arm 1; DRUG:zovaglutide Arm 2; DRUG:semaglutide
Results posted: FALSE

Registered primary outcomes

Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomization [from week 20 (randomization) to week 36]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.